Payment overview · 2025
General Payments
$1,237.53
64 reported records · 17 companies
Healthcare provider profile · identity verified
Ramesh Parchuri, M.D,
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1437224300
Verified facts
What the public records show
CMS Open Payments records show Ramesh Parchuri, M.D, received $1,237.53 in general payments during 2025 across 64 reported records.
GlaxoSmithKline, LLC. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Invega Sustenna, Jardiance, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $358.02 | 28.9% | 26 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $155.02 | 12.5% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $119.08 | 9.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $99.75 | 8.1% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $86.56 | 7.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.62 | 5.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $50.38 | 4.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.54 | 3.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.00 | 3.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.23 | 3.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $34.27 | 2.8% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $33.46 | 2.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.93 | 2.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.68 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.89 | 1.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.08 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.02 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,237.53 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $329.38 | 24 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $171.06 | 7 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $104.72 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $86.56 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.62 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.38 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.71 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $34.27 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $33.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.64 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 156 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 153 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
150 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
156 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 28 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 26 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1056 | 170 |
| Losartan Potassium | Losartan Potassium | 783 | 139 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 758 | 135 |
| Omeprazole | Omeprazole | 736 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 680 | 107 |
| Lisinopril | Lisinopril | 560 | 93 |
| Gabapentin | Gabapentin | 558 | 101 |
| Metformin Hcl | Metformin Hcl | 551 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 478 | 88 |
| Trazodone Hcl | Trazodone Hcl | 375 | 65 |
| Ibuprofen | Ibuprofen | 374 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 336 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 63 |
| Risperidone | Risperidone | 335 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 50 |
| Olanzapine | Olanzapine | 316 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 296 | 53 |
| Benztropine Mesylate | Benztropine Mesylate | 288 | 43 |
| Carvedilol | Carvedilol | 253 | 55 |
| Mirtazapine | Mirtazapine | 250 | 46 |
| Baclofen | Baclofen | 245 | 54 |
| Divalproex Sodium | Divalproex Sodium | 242 | 28 |
| Tramadol Hcl | Tramadol Hcl | 239 | 35 |
| Buspirone Hcl | Buspirone Hcl | 237 | 41 |
| Meloxicam | Meloxicam | 234 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 228 | 35 |
| Haloperidol | Haloperidol | 224 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 40 |
| Montelukast Sodium | Montelukast Sodium | 217 | 39 |
| Furosemide | Furosemide | 213 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 212 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 186 | 30 |
| Simvastatin | Simvastatin | 177 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 165 | 30 |
| Farxiga | Dapagliflozin Propanediol | 156 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 155 | 31 |
| Jardiance | Empagliflozin | 153 | 28 |
| Azithromycin | Azithromycin | 152 | 75 |
| Linzess | Linaclotide | 150 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 30 |
| Naproxen | Naproxen | 142 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 133 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 130 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 17 |
| Donepezil Hcl | Donepezil Hcl | 122 | 20 |
| Famotidine | Famotidine | 122 | 27 |
| Lorazepam | Lorazepam | 122 | suppressed |
| Nifedipine Er | Nifedipine | 121 | 24 |
| Celecoxib | Celecoxib | 117 | 32 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 114 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 16 |
| Alendronate Sodium | Alendronate Sodium | 105 | 24 |
| Aripiprazole | Aripiprazole | 105 | 16 |
| Amantadine | Amantadine Hcl | 104 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 94 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 93 | 34 |
| Eliquis | Apixaban | 92 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 14 |
| Sertraline Hcl | Sertraline Hcl | 89 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 27 |
| Nabumetone | Nabumetone | 84 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 81 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 78 | 22 |
| Trulicity | Dulaglutide | 75 | 12 |
| Vraylar | Cariprazine Hcl | 74 | suppressed |
| Cephalexin | Cephalexin | 73 | 61 |
| Januvia | Sitagliptin Phosphate | 73 | 15 |
| Potassium Chloride | Potassium Chloride | 73 | suppressed |
| Finasteride | Finasteride | 72 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 17 |
| Glipizide | Glipizide | 70 | 11 |
| Ozempic | Semaglutide | 70 | 12 |
| Ketoconazole | Ketoconazole | 67 | 13 |
| Levetiracetam | Levetiracetam | 64 | suppressed |
| Myrbetriq | Mirabegron | 64 | suppressed |
| Pregabalin | Pregabalin | 64 | 15 |
| Mupirocin | Mupirocin | 62 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 43 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 60 | 16 |
| Ammonium Lactate | Ammonium Lactate | 60 | suppressed |
| Allopurinol | Allopurinol | 58 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 57 | 11 |
| Ofloxacin | Ofloxacin | 53 | 38 |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 49 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Glimepiride | Glimepiride | 46 | 12 |
| Oxcarbazepine | Oxcarbazepine | 44 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 42 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 41 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 41 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Amoxicillin | Amoxicillin | 36 | suppressed |
| Carbamazepine Er | Carbamazepine | 36 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 29 |
| Topiramate | Topiramate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 32 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Single Use Swab | Alcohol Antiseptic Pads | 28 | 11 |
| Valsartan | Valsartan | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 22 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Valproic Acid | Valproic Acid | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,237.53 · 64 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, ARISTADA, BRIXADI, CAPLYTA, COBENFY, ELIQUIS, ENTRESTO, FANAPT, FARXIGA, GEMTESA, INVEGA SUSTENNA, JARDIANCE, Kerendia, LEQVIO, LOKELMA, LYBALVI, MOUNJARO, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error